9(3): e91174
High-potency, buffered mineral ascorbates provide therapeutic doses without causing severe gastrointestinal distress
While not always separately quantified in clinical trial data, bloatingcharacterized by a sensation of abdominal fullness, distension, or tightnessis recognized as part of the broader spectrum of gastrointestinal side effects associated with GLP-1 receptor agonists
Glia inflammation and cell death pathways drive disease progression in preclinical and early AD
Current pharmacological therapies, including cholinesterase inhibitors (ChEIs) (e.g., donepezil, rivastigmine, galantamine) and N-methyl-D-aspartate (NMDA) receptor antagonists (e.g., memantine), offer only modest symptomatic relief without altering disease progression (Butterfield and Halliwell, 2019)
Molecules , 19(11), 1906619077